---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-26-000118"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2026-10-29T11:06:28+00:00"
generated_at: "2026-10-29T11:10:11.057611+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q3 net sales $874.5M, +8.7% YoY; raises FY26 sales and adjusted EPS guidance

## Summary
- Q3 net sales $874.5M, up 8.7% YoY (organic +11.9%); diluted EPS $3.02, up 57.3%; adjusted diluted EPS $2.66, up 35.7%.
- FY2026 net sales guidance raised to $3.41B-$3.42B from $3.345B-$3.380B; adjusted diluted EPS raised to $9.38-$9.48 from $8.85-$9.05.
- HVP Components net sales $466.7M, up 19.7% (organic +20.3%) and 53% of total; Proprietary Products segment sales $728.8M, up 12.6%.
- West Vantage net sales $145.7M, down 7.3% (organic -6.6%); Standard Products $163.0M, up 2.9%; SmartDose 3.5mL sales $11.8M vs $29.8M prior-year.
- Repurchased $231M stock in Q3, $685M YTD; YTD operating cash flow $403M; FY26 capex guidance cut to $215M-$220M; Q4 dividend $0.26/share, up 18%.

## SEC filing metadata
- accession: 0000105770-26-000118
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2026-10-29T11:06:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577026000118/0000105770-26-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577026000118/wst-20261029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-26-000118
- JSON: https://secwatch.observer/filing/0000105770-26-000118.json
- Plain text: https://secwatch.observer/filing/0000105770-26-000118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.